Clinical Trials Browser

Phase 3 × Patient Preference × enzalutamide × Clear all

NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Terminated

Prostatic Neoplasms, Patient Preference